Sun Pharma gets USFDA nod for plaque psoriasis drug Ilumya
"With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis," Sun Pharma North America president said.
Sun Pharmaceutical Industries on Wednesday announced that it has received approval from the US Food and Drug Administration (FDA) for Ilumya (tildrakizumab-asmn) drug for the treatment plaque psoriasis.
"We have received USFDA approval for Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis. Psoriasis is a chronic immune disease that appears on the skin. It is a non-contagious disorder that speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form, affecting about 80 to 90 per cent of people living with psoriasis, is called plaque psoriasis," a company statement said.
"With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis," Sun Pharma North America president and chief executive officer Abhay Gandhi said.
The FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.
In addition to Ilumya, Sun Dermatology is comprised of several branded products indicated for the treatment of acne and actinic keratosis with a focus on other dermatologic conditions.